Sponsored

A feather in ImpediMed’s SOZO® cap: Clinical utility manuscript published

  • April 08, 2021 03:27 PM AEST
  • Sukriti
    Sukriti
    Author Sukriti
    80 Posts

    Sukriti is a Senior Financial Analyst at Kalkine Media Pty Ltd. She has experience of over 3.8 years in the field of finance, research, reporting standardisation and process developments. She has interned with brands like PepsiCo, Vogue, JBL and Dell...

A feather in ImpediMed’s SOZO<sup>®</sup> cap: Clinical utility manuscript published

Source: IPD’s announcement, Feb 2021

Summary

  • ImpediMed Limited (ASX:IPD) announced that the full peer-reviewed manuscript showing the clinical utility of SOZO® in monitoring heart failure (HF) patients has been published.
  • The publication is titled Clinical Utility of Fluid Volume Assessment in Heart Failure Patients Using Bioimpedance Spectroscopy.
  • This study is integral in achieving real-world proof for ImpediMed’s HF-Dex application, validates SOZO®’s ability to track patient fluid levels, and affirms that established normative range data can be useful in risk-stratifying patients.

ImpediMed Limited (ASX:IPD) has made substantial progress in the large and growing market of Heart Failure. Frontiers in Cardiovascular Medicine has published a full peer-reviewed manuscript, demonstrating the clinical utility of the Company’s SOZO® device.

MUST READ: ImpediMed reports key milestones across oncology, heart failure & renal failure in 1H21

ImpediMed’s latest publication

Frontiers in Cardiovascular Medicine publishes peer-reviewed research articles that are centred around cardiovascular medicine. It has published ImpediMed’s “Clinical Utility of Fluid Volume Assessment in Heart Failure Patients Using Bioimpedance Spectroscopy”.

The publication explains the BIS-derived HF-DexTM values, Extracellular Fluid, expressed as a percentage of Total Body Water (in a clinically relevant way). This can be used by physicians to assist in clinical risk stratification as well as fluid volume monitoring of HF patients.

RELATED READ: Impedimed’s SOZO ® Heart Failure Abstract Accepted For Poster Presentation At ACC

The paper concluded that-

  • BIS-measured ECF%TBW values were substantially higher in HF patients relative to adults without HF.
  • Three strata of ECF%TBW (normal, elevated & fluid overload) were labeled that may support in clinical risk stratification as well as examining fluid volume of HF patients.
  • The results indicate that as more data is collected, BIS measurements may offer a unique, additional tool to support clinical decision-making.

ALSO READ: How ImpediMed’s BIS device SOZO® is changing digital health landscape

Significance of the study

BIS technology has been validated for fluid monitoring. However, the absence of established reference ranges in HF has limited its efficiency for workflow implementation. Besides, the usage of HF-Dex in BIS demonstrates the ability to examine as well as follow volume status in HF.

The current study comes into limelight as it-

  • Explains the usage of a HF-Dex scale, distinguishing normal from abnormal extracellular fluid.
  • Illustrates the potential utility as a tool to aid in clinical decision-making for HF patients.
  • Suggests that finding subclinical fluid overload would be valuable in the risk factor stratification for HF patients in acute and chronic settings.

IPD traded with a volume of over 1.8 million shares on 8 April 2021 and quoted $0.12.

INTERESTING READ: Will ImpediMed’s growing business continue in the same vein?

 

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK